Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of RESVERLOGIX CORP
No Price
Closing Price XTSE 28.04.2026:
0,10 CAD
28.04.2026 20:00
Current Prices from RESVERLOGIX CORP
Exchange
Ticker
Currency
Last Trade
Price
Daily Change
UTC
RVXCF
USD
28.04.2026 20:00
0,07 USD
0,00 USD
TSX
RVX.TO
CAD
28.04.2026 13:30
0,10 CAD
-0,005 CAD
-4,76 %
Share Float & Liquidity
Free Float70,54 %
Shares Float223,03 M
Shares Outstanding316,17 M
Company Profile for RESVERLOGIX CORP Share
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. It is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada. The company is headquartered in Calgary, Canada.
